By Regenerative Medicine China · Published and sources checked · Patient information. Individual treatment and study eligibility require the responsible clinical team’s assessment.
Can I ask about a China clinical trial while taking daraxonrasib (RMC-6236)?
You can discuss future trial options and request a preliminary records review while receiving daraxonrasib. Eligibility depends on the specific study and cohort: some exclude previous RAS-directed therapy. A washout does not remove that history. Any treatment change must be coordinated by your treating oncologist and the trial team.
Daraxonrasib is broader than a G12D-specific drug
Daraxonrasib, also called RMC-6236, is a RAS(ON) multi-selective inhibitor. Its classification differs from G12D-selective agents such as zoldonrasib. Give the reviewing team the actual drug name and your molecular report; taking daraxonrasib does not itself establish a KRAS G12D mutation. Revolution Medicines explains these drug classes.
On August 26, 2026, the US FDA approved daraxonrasib, branded RASONQUE, for adults with metastatic pancreatic adenocarcinoma after at least one systemic treatment, or when multiagent systemic therapy is unsuitable. This is a US approval; it does not establish approval, supply or trial access in China. FDA approval notice.
Check the prior-treatment rule before planning a transition
Previous RAS-directed treatment can affect eligibility even after the medicine has been stopped. For example, the China phase III GFH375 study NCT07262567, updated August 14, 2026, excludes previous KRAS G12D-directed or pan-RAS/KRAS therapy. Disclose daraxonrasib explicitly and ask the investigator to apply the current protocol.
The zoldonrasib study NCT06040541 also excludes previous direct RAS-targeted treatment, including multi-RAS inhibitors. Its combination arm containing daraxonrasib does not mean someone already receiving daraxonrasib can enter. The record checked here listed US sites, so it should not be presented as a China access route.
A washout is a separate requirement
A washout is the interval a protocol requires between treatments. In NCT07262567, the published interval for other anticancer therapy is 28 days or five half-lives, whichever is shorter. The ASP3082 study NCT05382559 lists a different interval for prior antineoplastic therapy: 21 days or five half-lives, whichever is shorter. These are examples from particular records, not a timetable for an individual patient.
Meeting an interval does not override an exclusion based on previous drug exposure. Recovery from side effects and other screening requirements also matter. Do not stop, skip or reduce daraxonrasib to create a washout yourself. Your oncologist and the receiving trial team must coordinate any proposed transition.
Ask about the exact cohort, not just the drug name
Rules can differ within a study. NCT05382559 generally excludes prior G12D-directed or relevant pan-RAS treatment, but its public summary includes an exception for previous G12D inhibitor or degrader treatment in a combination cohort. That wording alone does not confirm eligibility after daraxonrasib, identify a suitable pancreatic cancer cohort, or establish a China opening. The study team must resolve those questions.
If one study excludes prior RAS treatment, ask your oncologist whether other studies with different eligibility rules deserve review. Avoid assuming that all future trials are closed, or that changing drug class guarantees acceptance.
Use prescreening to answer practical questions
A preliminary review can clarify whether further assessment is worthwhile; it is not enrollment. Ask which protocol version and cohort were checked, whether prior daraxonrasib is permitted, what evidence of disease status is required, and which records are missing. The NCI trial-search guide recommends discussing the options with your doctor and contacting the trial team to assess likely eligibility.
For China, request dated confirmation from the hospital or study team about the local cohort status, capacity and assessment process before arranging travel. A registry marked recruiting does not guarantee a place. Clarify visit frequency, language support and expected costs, and involve the existing study team if your current treatment is within a trial.
Prepare for your review
- Pathology and full molecular report, including the exact KRAS variant if present.
- Treatment timeline naming daraxonrasib and every previous anticancer therapy.
- Recent scan reports, relevant laboratory results and current side effects.
- Treating oncologist contact details and, where applicable, current trial details.
- The proposed trial identifier, hospital, cohort and date of eligibility feedback.
Common questions
Does prescreening mean I should change treatment?
No. It can support future planning while your treating team assesses current treatment. A records review does not establish that a switch would help.
Can a longer washout overcome a prior-RAS exclusion?
No. Time since the last treatment and whether that treatment is permitted are separate eligibility questions.
Can a service guarantee China trial enrollment?
No. The hospital investigator and study team determine eligibility and enrollment under the protocol; a preliminary review cannot reserve a place.
Sources and evidence boundaries
- FDA: daraxonrasib approval, August 26, 2026
- Revolution Medicines Medical Affairs: RAS inhibitor classes and geographic approval statement
- ClinicalTrials.gov: GFH375 phase III, NCT07262567
- ClinicalTrials.gov: zoldonrasib, NCT06040541
- ClinicalTrials.gov: ASP3082, NCT05382559
- National Cancer Institute: Steps to Find a Clinical Trial
Registry status and local access can change. A public listing, molecular match or source citation is not a hospital partnership, a reserved place or confirmation of eligibility. Published research and overseas approvals should be interpreted in their stated setting. This guide does not present an RMC patient outcome.